Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mechanisms of acquired resistance to osimertinib are more heterogeneous than those to first- and second-generation TKIs, including EGFR C797S, acquired KRAS, and targetable gene fusions.
“mechanisms of acquired resistance to osimertinib are more heterogeneous, and include EGFR C797S, acquired KRAS, and targetable gene fusions.”
From Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [98]
Cited by
Sorted by citations
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411 · see citing works
Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115 · see citing works
- Authors
- Papadimitrakopoulou, V. A., Wu, Y.-L., Han, J.-Y., Ahn, M.-J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C.-H., Bulusu, K. C., Laus, G., Collins, B., Barrett, J. C., Chmielecki, J., & Mok, T. S. K.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Guangdong General Hospital (CN)
- National Cancer Center (KR)
- Samsung Medical Center (KR)
- Emory University (US)
- Austin Health (AU)
- Kyushu University (JP)
- National Taiwan University (TW)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Chinese University of Hong Kong (HK)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Pages
- viii741
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2898359687
- Cited by
- 252
- References
- 0
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 19 · 2023: 34 · 2022: 56 · 2021: 58 · 2020: 33 · 2019: 24 · 2018: 2
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- osimertinib, T790M mutation, advanced non-small cell lung cancer, acquired drug resistance, circulating tumor DNA, AURA3 trial, EGFR tyrosine kinase inhibitors, platinum-based doublet chemotherapy, second-line therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
